phase i/iia trial to investigate bi 6727 (volasertib) as monotherapy or in combination with cytarabine in acute myeloid leukaemia

Conditions: Leukemia, Myeloid, Acute

Summary: the trial will be performed in two parts, a phase i part and a phase iia part. in the phase i part of the trial, bi 6727 will be investigated as monotherapy and in combination with low dose cytarabine (ld-ara-c) in patients with relapsed/refractory aml that are not eligible for intensive treatment. the dose of bi 6727 will be escalated to determine the maximum tolerated dose (mtd) of bi 6727 monotherapy and bi 6727 in combination with ld-ara-c in aml patients. in the phase iia part, the combination of bi 6727 at mtd with ld-ara-c and ld-ara-c monotherapy will be investigated to explore the efficacy of the combination schedule in comparison to ld-ara-c monotherapy in previously untreated aml patients that are not eligible for intensive treatment.


Eligibility criteria:
inclusion criteria: male or female adult with relapsed/refractory aml ineligible for intensive treatment (phase i part only) male or female adult with previously untreated aml ineligible for intensive treatment (phase iia part only) confirmed diagnosis of aml according to the who definition (except for acute promyelocytic leukaemia, apl) patient is eligible for ld-ara-c treatment life expectancy \> 3 months eastern co-operative oncology group (ecog, r01-0787) performance score \<=2 at screening signed written informed consent consistent with international conference on harmonisation, good clinical practice (ich-gcp) and local legislation exclusion criteria: previously untreated aml (phase i part only) relapsed or treatment refractory aml (phase iia part only) patient with apl (aml subtype m3 according to the french-american-british (fab) classification) hypersensitivity to one of the trial drugs or the excipients other malignancy requiring treatment symptomatic central nervous system involvement clinically relevant qt prolongation (e.g. long qt syndrome, qtcf\>470 ms) aspartate amino transferase (ast) or alanine amino transferase (alt) greater than 2.5 times the upper limit of normal (uln), or ast or alt greater than 5 times the uln in case of known leukaemia liver involvement prothrombin time (pt) \> 1.5 x uln for subjects not on therapeutic vitamin k antagonists (phenprocoumon, warfarin) bilirubin greater than 1.5 mg/dl (\> 26 mcmol/l) serum creatinine greater than 2.0 mg/dl concomitant intercurrent illness, which would compromise the evaluation of efficacy or safety of the trial drug, e.g. active severe infection, unstable angina pectoris, cardiac arrhythmia or severe heart failure/cardiac insufficiency. psychiatric illness or social situation that would limit compliance with trial requirements concomitant therapy, which is considered relevant for the evaluation of the efficacy or safety of the trial drug contraindications for cytarabine treatment according to the spc female patients of childbearing potential who are sexually active and unwilling to use a medically acceptable method of contraception during the trial, i.e. combination of two forms of effective contraception (hormonal contraception, intrauterine device, condom with spermicide, etc.). male patients with partners of childbearing potential who are unwilling to use condoms in combination with a second medically acceptable method of contraception during the trial pregnant or nursing female patients patient unable to comply with the protocol